tarlatamab Imdelltra
Selected indexed studies
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. (N Engl J Med, 2025) [PMID:40454646]
- Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. (J Clin Oncol, 2023) [PMID:36689692]
- Tarlatamab: First Approval. (Drugs, 2024) [PMID:39023700]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Antibodies to watch in 2025. (2025) pubmed
- Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. (2023) pubmed
- Tarlatamab: First Approval. (2024) pubmed
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. (2025) pubmed
- Tarlatamab. (2006) pubmed
- PMID:40294183 (2025) pubmed
- PMID:40758804 (2025) pubmed
- Tarlatamab (Imdelltra) for small cell lung cancer. (2024) pubmed
- AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. (2021) pubmed
- Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases. (2025) pubmed